MedTrace Logo

A Non Interventional Study to Investigating the Ratio of Mis-diagnosed Bipolar Symptoms in Patient With Major Depressive Disorder (MDD)

NCT01344733 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 660

Last updated 2012-03-23

No results posted yet for this study

Summary

The study will only detect hypomanic symptoms in treatment resistant MDD patients by mean of HCL-32 administration. Further re-evaluation of MDD diagnosis is not a direct aim of the study. No efficacy and tolerability of pharmacological treatments will be assessed. Patients matching inclusion and exclusion criteria will be enrolled consecutively; each investigator will include the first 10 to 40 patients that will be visited as treatment resistant MDD.

Conditions

Sponsors & Collaborators

Principal Investigators

  • Dr. Mauro Carta · A.O.U. Universitaria di Cagliari

  • Dr. Gino Montagnani · Astrazeneca Italy

  • Dr. Raffaele Sabia · Astrazeneca Italy

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-05-31
Primary Completion
2012-03-31
Completion
2012-03-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01344733 on ClinicalTrials.gov